Key result
Advances in imaging and targeted therapies improve cardiac amyloidosis diagnosis and management in HFpEF.
Why the study?
Cardiac amyloidosis is a rare organic heart disease with clinical findings related to amyloid deposition in cardiac structures, requiring better electrocardiographic characterization.
Supports amyloid screening in unexplained HFpEF; leaves open optimal integration of targeted therapies into practice.
CARDIAC amyloidosis is a distinct although rare type of organic heart disease in which the clinical findings are believed to be related to the variable deposition of amyloid in the pericardium, valves, myocardium and smaller blood vessels. 1 The purposes of this report are (1) to present 2 cases of cardiac amyloidosis in which electrocardiograms suggested the diagnosis of myocardial infarction, (2) to review the available electrocardiographic data on cardiac amyloidosis and (3) to comment on the relationship of the electrocardiographic findings to the pathologic changes in the myocardium. REPORT OF CASES CASE 1. —A. B., a 67 year old widow, was admitted to the Beth Israel hospital on Aug. 30, 1946, because of the swelling of the abdomen of two weeks' duration. Sixteen months before her entry she was seen in the outpatient department because of headache. Physical examination at that time revealed a blood pressure of 210 systolic
No takes yet. Share an insight, caveat, or question.
Stanford Wessler (1948) conducted a review in Cardiac amyloidosis. Cardiac amyloidosis is an increasingly recognized etiology of heart failure with preserved ejection fraction, with recent advances in non-invasive imaging, genetic testing, and targeted therapies improving diagnosis and management.
Synapse has enriched one closely related paper. Consider it for comparative context: